The test manufactured by Response Biomedical runs on the new RAMP 200 Reader and will be marketed and sold worldwide exclusively by 3M Health Care as the 3M rapid detection flu A+B test.
The rapid detection flu A+B test is a qualitative immunochromatographic assay indicated for use as an in vitro diagnostic product with the 3M Rapid Detection Reader to identify the presence of flu A and flu B nucleoprotein antigen in nasopharyngeal swab, nasopharyngeal aspirate, nasal wash or aspirate specimens. Measurement of flu A and flu B aids in the differential diagnosis of influenza viral infections through use of this test.
Wayne Kay, CEO of Response Biomedical, said: “We believe with 3M Health Care’s strong marketing and distribution network, we can quickly introduce this product to the worldwide market. FDA clearance in the US market is an important step toward this goal.”